A case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.
It's essential to integrate point-of-care testing devices cautiously alongside traditional laboratory tests to ensure robust diabetes management.
Blood-based biomarker tests are revolutionizing Alzheimer's diagnostic testing and management of Alzheimer’s disease.
A new survey reveals declining cancer screening rates among U.S. adults, but shows strong interest in innovative screening methods.
Quest Diagnostics has launched a new PCR-based diagnostic test for the Oropouche virus, enhancing preparedness for this emerging disease.
Juniper Genomics has launched publicly to offer a next-generation embryo screening platform that aims to improve IVF outcomes.
rex Laboratories has launched BiomeBurden, a comprehensive test that evaluates immune responses to microbial, yeast, and mold triggers.
University of Tokyo researchers have developed a non-invasive, AI-powered imaging system that tracks platelet activity in real time.
A Finnish study reveals that Alzheimer’s-related blood biomarkers can be detected in middle age, potentially spotting the disease sooner.
Two studies demonstrate how AI models can significantly improve early detection of type 1 diabetes, enabling earlier intervention.
A pilot program using Healthy.io’s FDA-cleared smartphone-powered Minuteful Kidney test significantly improved CKD screening and diagnosis.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A new study identifies three sepsis subtypes and highlights ELL2 as a promising biomarker for early diagnosis and prognosis.